We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Can Veeva's Vault R&D Keep Its Lead Amid Rising AI Competition?
Read MoreHide Full Article
Key Takeaways
{\"0\":\"Vault R&D drives customer expansion and adoption across clinical, safety, and regulatory domains.\",\"1\":\"VEEV is embedding AI to support tasks like document drafting and case processing in R&D workflows.\",\"2\":\"AI-native rivals and evolving tech stacks are challenging VEEV\'s lead in a fast-changing R&D landscape.\"}
Veeva Systems (VEEV - Free Report) is leaning heavily on its Vault R&D platform to anchor long-term growth, and so far, it’s working. The platform, which spans clinical, regulatory, quality, and safety domains, continues to see healthy customer expansion and product adoption. In its latest update, management highlighted strength in areas like Vault Safety and Vault Clinical, where digitization and automation are reshaping how trials are run and managed. Veeva’s deep relationships with top pharma clients, combined with ongoing investments in domain-specific AI, are helping it evolve from a software vendor into a strategic infrastructure partner across the drug development lifecycle.
Still, the landscape is changing. AI-native challengers are emerging with new ways to approach trial design, drug safety monitoring and data workflows. While Veeva is embedding AI across its R&D suite, supporting functions like regulatory document drafting and case processing, it’s now competing not only with traditional players, but also with younger, more specialized platforms. The company’s scale, focus on compliance, and integration depth remain strong differentiators, but investors will want to see continued innovation and proof that Veeva can hold its lead in an increasingly dynamic and data-driven market.
Peers Update
A name to watch in this space is Dassault Systemes (DASTY - Free Report) , which operates Medidata, a major provider of cloud-based solutions for clinical trials. Medidata is expanding its capabilities through AI-powered tools for trial planning and patient recruitment. While its approach differs from Veeva’s, both companies are addressing similar challenges in trial efficiency and data quality. Dassault also brings strength in simulation and manufacturing through its broader 3DEXPERIENCE platform, offering customers a more holistic lens on product development.
Another adjacent player is Schrodinger Inc. (SDGR - Free Report) , known for its AI-driven drug discovery platform. While Schrödinger operates earlier in the R&D value chain, its traction with biopharma clients reflects the growing demand for specialized, cloud-first tools in life sciences. As R&D organizations diversify their tech stacks, companies like Schrödinger could complement, not necessarily compete with, platforms like Veeva, particularly in environments where speed and innovation are prioritized.
Veeva Systems’ Price Performance, Valuation and Estimates
Shares of VEEV have gained 35.4% in the year-to-date period compared with the industry’s growth of 10.7%.
Image Source: Zacks Investment Research
From a valuation standpoint, Veeva trades at a forward price-to-sales ratio of 14.2, above the industry average. VEEV carries a Value Score of D.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for VEEV’s fiscal 2026 earnings implies a 15.8% rise from the year-ago period.
Image: Bigstock
Can Veeva's Vault R&D Keep Its Lead Amid Rising AI Competition?
Key Takeaways
Veeva Systems (VEEV - Free Report) is leaning heavily on its Vault R&D platform to anchor long-term growth, and so far, it’s working. The platform, which spans clinical, regulatory, quality, and safety domains, continues to see healthy customer expansion and product adoption. In its latest update, management highlighted strength in areas like Vault Safety and Vault Clinical, where digitization and automation are reshaping how trials are run and managed. Veeva’s deep relationships with top pharma clients, combined with ongoing investments in domain-specific AI, are helping it evolve from a software vendor into a strategic infrastructure partner across the drug development lifecycle.
Still, the landscape is changing. AI-native challengers are emerging with new ways to approach trial design, drug safety monitoring and data workflows. While Veeva is embedding AI across its R&D suite, supporting functions like regulatory document drafting and case processing, it’s now competing not only with traditional players, but also with younger, more specialized platforms. The company’s scale, focus on compliance, and integration depth remain strong differentiators, but investors will want to see continued innovation and proof that Veeva can hold its lead in an increasingly dynamic and data-driven market.
Peers Update
A name to watch in this space is Dassault Systemes (DASTY - Free Report) , which operates Medidata, a major provider of cloud-based solutions for clinical trials. Medidata is expanding its capabilities through AI-powered tools for trial planning and patient recruitment. While its approach differs from Veeva’s, both companies are addressing similar challenges in trial efficiency and data quality. Dassault also brings strength in simulation and manufacturing through its broader 3DEXPERIENCE platform, offering customers a more holistic lens on product development.
Another adjacent player is Schrodinger Inc. (SDGR - Free Report) , known for its AI-driven drug discovery platform. While Schrödinger operates earlier in the R&D value chain, its traction with biopharma clients reflects the growing demand for specialized, cloud-first tools in life sciences. As R&D organizations diversify their tech stacks, companies like Schrödinger could complement, not necessarily compete with, platforms like Veeva, particularly in environments where speed and innovation are prioritized.
Veeva Systems’ Price Performance, Valuation and Estimates
Shares of VEEV have gained 35.4% in the year-to-date period compared with the industry’s growth of 10.7%.
Image Source: Zacks Investment Research
From a valuation standpoint, Veeva trades at a forward price-to-sales ratio of 14.2, above the industry average. VEEV carries a Value Score of D.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for VEEV’s fiscal 2026 earnings implies a 15.8% rise from the year-ago period.
Image Source: Zacks Investment Research
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.